PDSB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now for an impatient trader. The chart is in a clear downtrend and price is sitting on first support (~0.85) with weakening momentum (negative, expanding MACD). Options positioning is extremely call-heavy (bullish/speculative), but there are no fresh news catalysts this week to force an immediate upside move, and fundamentals show continued loss expansion. Given the lack of Intellectia buy signals today, the risk/reward is not attractive for an immediate entry at pre-market levels.
Trend is bearish: SMA_200 > SMA_20 > SMA_5 confirms a sustained downtrend. Momentum is deteriorating with MACD histogram at -0.01 and negatively expanding. RSI_6 at 31.586 is near oversold, which can support a bounce, but it is not a confirmed reversal signal. Price is testing key support: S1=0.85 (pre-market ~0.8525). A clean break below 0.85 increases downside risk toward S2=0.798. Upside levels to reclaim are Pivot=0.935 and R1=1.019; without those, rallies are more likely to be sold into.
Wall Street remains bullish overall (Buy ratings) with thesis centered on PDS0101 clinical progress and improved probability of success in head & neck cancer (per H.C. Wainwright). The stock is also technically near a major support zone (~0.85), which can produce short-term bounce attempts. Options positioning is heavily call-skewed, implying traders are leaning toward upside.
Financial profile remains loss-making with worsening YoY net income and EPS in the latest quarter, increasing dilution/financing overhang risk. No supportive signal from Intellectia modules today (no AI Stock Picker buy, no SwingMax entry).
Latest reported quarter: 2025/Q3. Revenue remained effectively 0 (0.00% YoY). Net income fell to -$9.01M (down 16.01% YoY, i.e., losses widened). EPS dropped to -$0.19 (down 34.48% YoY). Overall: no top-line traction and accelerating per-share losses, which is a negative near-term backdrop for an impatient buyer.
Recent analyst trend: still positive on rating but mixed on targets. B. Riley (2025-11-25) kept Buy but cut PT from $5 to $3, signaling tempered near-term expectations despite calling valuation attractive. H.C. Wainwright (2025-11-13) reiterated Buy and raised PT from $13 to $15 on improved survival-data confidence. Wall Street pros: perceived clinical upside and attractive valuation framing. Cons: microcap biotech execution/financing risk, ongoing losses, and the chart trend is currently working against the bull thesis.
